GlassScriptPhysician profile
Mylan Kohler
NPI 1457521866
$17,975.48
in general payments reported to CMS, 2019-2025
33 companies · $2,885 in 2025
The $2,885 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $1,411 · 2021: $2,465 · 2022: $3,066 · 2023: $3,700 · 2024: $2,522 · 2025: $2,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,050 · Education: $57.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,049.50 |
| Education | $57.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,068.37 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,899.65 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,526.57 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,489.43 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,452.30 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,124.06 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $1,107.68 | 2020-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $1,073.17 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $925.08 | 2021-2025 | |
| Corium, LLC | $914.99 | 2022-2025 | Azstarys |
| Allergan, INC. | $623.65 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $606.21 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $531.31 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $424.89 | 2023-2025 | Auvelity |
| Tris Pharma INC | $357.88 | 2019-2025 | Dyanavel Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $317.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $312.15 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $240.88 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $193.33 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $127.49 | 2022-2024 | Spravato, Invega, Invega Trinza |
| Indivior INC. | $118.81 | 2022-2023 | Perseris |
| Almatica Pharma LLC | $116.58 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Bausch Health US, LLC | $87.44 | 2022-2023 | Wellbutrin, Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $87.19 | 2019-2021 | |
| Noven Therapeutics, LLC | $54.49 | 2021-2024 | Secuado, Xelstrym |
| Jazz Pharmaceuticals INC. | $50.99 | 2019-2021 | |
| Sage Therapeutics, LLC | $40.07 | 2023-2024 | |
| Neos Therapeutics, LP | $29.09 | 2019 | |
| Eisai INC. | $21.39 | 2022 | |
| Noven Pharmaceuticals, INC. | $20.54 | 2021 | |
| Adlon Therapeutics L.P. | $14.04 | 2020 | |
| Acadia Pharmaceuticals INC | $12.58 | 2019 | |
| Neuronetics, INC. | $5.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mylan Kohler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.